Ophthalmology最新文献

{"title":"Gargantua, The Scholarship of Synthesis and the Evolution of the Ophthalmology Family Journals","authors":"Russell N. Van Gelder MD, PhD, Laura E. Downie BOptom, PhD","doi":"10.1016/j.ophtha.2024.11.014","DOIUrl":"10.1016/j.ophtha.2024.11.014","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 1","pages":"Pages 12-13"},"PeriodicalIF":13.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"This Issue at a Glance","authors":"Sandeep Ravindran PhD","doi":"10.1016/j.ophtha.2024.11.011","DOIUrl":"10.1016/j.ophtha.2024.11.011","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 1","pages":"Page 1"},"PeriodicalIF":13.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Unusual Pigmented Lesion","authors":"Shambhawi Thakur MS , Lucie Y. Guo MD, PhD , Prithvi Mruthyunjaya MD, MHS","doi":"10.1016/j.ophtha.2024.01.030","DOIUrl":"10.1016/j.ophtha.2024.01.030","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 1","pages":"Page e14"},"PeriodicalIF":13.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139983442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extraocular Muscle Inflammation and Strabismus in a Patient with Zoster Ophthalmicus","authors":"Jonathan Thomas BS , David Leake MD , Mary Kelly Green MD","doi":"10.1016/j.ophtha.2024.01.015","DOIUrl":"10.1016/j.ophtha.2024.01.015","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 1","pages":"Page e9"},"PeriodicalIF":13.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140294084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies","authors":"Jee Myung Yang MD, PhD , Se Yong Jung MD , Min Seo Kim MD , Seung Won Lee MD, PhD , Dong Keon Yon MD , Jae Il Shin MD, PhD , Joo Yong Lee MD, PhD","doi":"10.1016/j.ophtha.2024.07.008","DOIUrl":"10.1016/j.ophtha.2024.07.008","url":null,"abstract":"<div><h3>Purpose</h3><div>To analyze cardiovascular and cerebrovascular adverse drug reactions (ADRs) after intravitreal anti–VEGF (aflibercept, bevacizumab, brolucizumab, and ranibizumab) treatment.</div></div><div><h3>Participants</h3><div>VigiBase, a World Health Organization (WHO) global safety report database.</div></div><div><h3>Design</h3><div>Pharmacovigilance study.</div></div><div><h3>Methods</h3><div>The individual case safety reports (ICSRs) of cardiovascular and cerebrovascular ADRs after intravitreal anti-VEGF treatment were compared with those reported in the full database. From 2004 to 2023, there were 23 129 ADRs after intravitreal anti-VEGF therapy and 25 015 132 ADRs associated with any drug (full database).</div></div><div><h3>Main Outcome Measures</h3><div>The reporting odds ratio (ROR) and information components (ICs) were calculated, and the 95% lower credibility interval end point of the information component (IC<sub>025</sub>) was used for disproportionate Bayesian reporting. Inter-drug comparisons were performed using the ratio of odds ratio (rOR).</div></div><div><h3>Results</h3><div>Compared with the full database, anti-VEGFs were associated with an increased reporting of myocardial infarction (IC<sub>025</sub> 0.75; ROR: 1.78 [95% CI, 1.70–1.86]), angina pectoris (IC<sub>025</sub> 0.53; ROR: 1.61 [95% CI, 1.47–1.77]), arrhythmias including atrial fibrillation, atrial flutter, ventricular fibrillation, supraventricular tachycardia (all IC<sub>025</sub> > 0, ROR>1), hypertension (IC<sub>025</sub> 2.22; ROR: 4.91 [95% CI, 4.82–5.01]), and hypertensive crisis (IC<sub>025</sub> 1.97; ROR: 4.49 [95% CI, 4.07–4.97]). Moreover, anti-VEGFs were associated with a higher reporting of cerebrovascular ADRs such as cerebral infarction (IC<sub>025</sub> 4.34; ROR: 23.19 [95% CI, 22.10–24.34]), carotid artery stenosis (IC<sub>025</sub> 1.85; ROR: 5.24 [95% CI, 3.98–6.89]), cerebral hemorrhage (IC<sub>025</sub> 2.29; ROR: 5.38 [95% CI, 5.03–5.76]), and subarachnoid hemorrhage (IC<sub>025</sub> 1.98; ROR: 4.81 [95% CI, 4.14–5.6]). Inter-drug comparison indicated that compared with ranibizumab, patients receiving aflibercept showed overall under-reporting of cardiovascular and cerebrovascular ADRs such as myocardial infarction (rOR 0.55 [95% CI, 0.49–0.52]), atrial fibrillation (rOR 0.28 [95% CI, 0.23–0.35]), cerebrovascular accident (rOR, 0.15 [95% CI, 0.14–0.17]), and cerebral hemorrhage (rOR, 0.51 [95% CI, 0.40–0.65]).</div></div><div><h3>Conclusions</h3><div>In this pharmacovigilance case-noncase study, there was significantly increased reporting of cardiovascular and cerebrovascular ADRs after intravitreal anti-VEGF treatment. Although ranibizumab may exhibit superior systemic safety regarding its biological characteristics, it is crucial not to overlook the occurrence of cardiovascular and cerebrovascular ADRs considering its higher reporting rate than bevacizumab or aflibercept.</div></div><div><h3>Financial Disclosure(s)</","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 1","pages":"Pages 62-78"},"PeriodicalIF":13.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reversal of Pharmacologically Induced Mydriasis with Phentolamine Ophthalmic Solution","authors":"Jay S. Pepose MD, PhD ,&nbsp;David Wirta MD ,&nbsp;David Evans OD ,&nbsp;Barbara Withers PhD ,&nbsp;Kavon Rahmani BS ,&nbsp;Audrey Lazar BS ,&nbsp;Drey Coleman BS ,&nbsp;Ronil Patel MS ,&nbsp;Reda Jaber MD ,&nbsp;Mina Sooch MBA ,&nbsp;Mitchell Brigell PhD ,&nbsp;Konstantinos Charizanis PhD","doi":"10.1016/j.ophtha.2024.09.010","DOIUrl":"10.1016/j.ophtha.2024.09.010","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the safety and efficacy of 0.75% phentolamine ophthalmic solution (POS), an α-adrenergic antagonist, in reversal of pharmacologically induced mydriasis.</div></div><div><h3>Design</h3><div>Two phase 3, multicenter, placebo-controlled, randomized, double-masked clinical trials in healthy participants.</div></div><div><h3>Participants</h3><div>Five hundred fifty-three healthy 12- to 80-year-old participants were randomized 1:1 (MIRA 2) and 2:1 (MIRA 3) to receive either POS or placebo eye drops in both eyes.</div></div><div><h3>Methods</h3><div>Participants received POS or placebo administered 1 hour after mydriasis, induced by instillation of either 2.5% phenylephrine, 1% tropicamide, or 1% hydroxyamphetamine / 0.25% tropicamide.</div></div><div><h3>Main Outcome Measures</h3><div>Percent of participants returning to within 0.2 mm of baseline pupil diameter in study eye 90 minutes after POS administration. Safety measures included treatment-emergent adverse events and tolerability measures, including conjunctival hyperemia.</div></div><div><h3>Results</h3><div>A total of 553 participants were randomized to treatment with placebo (n = 215) or POS (n = 338). A statistically significant greater percentage of participants treated with POS showed reversal of mydriasis at 90 minutes compared to placebo (MIRA 2: 48.9% vs. 6.6% [<em>P</em> &lt; 0.0001]; MIRA 3: 58% vs. 6% [<em>P</em> &lt; 0.0001]) and as early as 60 minutes (MIRA 2: 27.7% vs. 2.2% [<em>P &lt;</em> 0.0001]; MIRA 3: 42% vs. 2% [<em>P</em> &lt; 0.0001]). Between 28% and 34% of participants receiving placebo did not returned to baseline PD at 24 hours after pharmacologic dilation compared with 8% to 11% of patients treated with POS (<em>P</em> &lt; 0.0001).</div></div><div><h3>Conclusions</h3><div>Treatment with POS reduced PD within 60 to 90 minutes, with a statistically significant time savings of 5 to 6 hours to return to baseline PD compared with placebo. One or 2 drops of POS rapidly reversed mydriasis in all participants regardless of mydriatic agent or iris color. More participants receiving POS reported a benefit in the resolution of visual symptoms caused by pharmacologically induced mydriasis compared with placebo, with statistically significant differences noted as early as 1 hour. The safety profile was favorable, with the most common adverse effects being mild transient conjunctival hyperemia (11.2%), instillation site discomfort (10.9%), and dysgeusia (3.6%).</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 1","pages":"Pages 79-91"},"PeriodicalIF":13.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Rate of Re-treatment in Patients Treated with Teprotumumab","authors":"Shoaib Ugradar MD ,&nbsp;Emanuil Parunakian BS ,&nbsp;Emil Malkhasyan BS ,&nbsp;Carolina A. Chiou MD ,&nbsp;Hannah L. Walsh BS ,&nbsp;Joseph Tolentino BS ,&nbsp;Sara T. Wester MD ,&nbsp;Suzanne K. Freitag MD ,&nbsp;Raymond S. Douglas MD, PhD","doi":"10.1016/j.ophtha.2024.07.018","DOIUrl":"10.1016/j.ophtha.2024.07.018","url":null,"abstract":"<div><h3>Purpose</h3><div>To determine the rate of re-treatment in patients who receive a full course of teprotumumab therapy for thyroid eye disease (TED) and drivers of re-treatment.</div></div><div><h3>Design</h3><div>Multicenter retrospective study.</div></div><div><h3>Participants</h3><div>All patients who received a full course of treatment and had available data at 1 year after initial treatment were included.</div></div><div><h3>Methods</h3><div>Charts were reviewed for the following information: age, sex, months since diagnosis of TED, smoking status, and prior treatments. Further, the clinical activity score (CAS), proptosis, and the Gorman diplopia score were reviewed at baseline, at the end of the first course, and at baseline for the second course in those who received it. A logistic regression model was created to review the drivers of re-treatment.</div></div><div><h3>Main Outcome Measures</h3><div>Rate of re-treatment and the drivers of re-treatment.</div></div><div><h3>Results</h3><div>One hundred nineteen patients were included from 3 centers across the United States. The overall re-treatment rate was 24% (29/119). No difference was found among the 3 sites (<em>P</em> = 0.6). In univariable analyses, at baseline, no difference was found in proptosis (<em>P</em> = 0.07), diplopia score (<em>P</em> = 0.4), or duration of TED (<em>P</em> = 0.4) between patients who were re-treated and those not re-treated. From the re-treated group, 82% showed a significant proptosis response (≥ 2-mm reduction from baseline) after the initial course, whereas 68% of patients who were not re-treated showed a clinically significant proptosis response (<em>P</em> = 0.16). The mean ± standard deviation difference between the end of the first treatment and at baseline before the second treatment (in those who received it) was 2 ± 2 for CAS, 2 ± 4 mm for proptosis, and 1 ± 1 for diplopia score. Age was the only significant driver of re-treatment (<em>P</em> &lt; 0.05). Re-treated patients were 7 years older than patients who were not re-treated (60 years vs. 53 years; <em>P</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>In patients receiving a full course of teprotumumab therapy, the rate of re-treatment was 24%. Age was the only driver of re-treatment.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 1","pages":"Pages 92-97"},"PeriodicalIF":13.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141734751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between Blood Pressure and Rates of Glaucomatous Visual Field Progression","authors":"Richard Donkor MSc, PhD,&nbsp;Alessandro A. Jammal MD, PhD,&nbsp;David S. Greenfield MD","doi":"10.1016/j.ophtha.2024.07.026","DOIUrl":"10.1016/j.ophtha.2024.07.026","url":null,"abstract":"<div><h3>Purpose</h3><div>To examine the relationship between systemic arterial blood pressure (BP) and the rate of change in standard automated perimetry (SAP) in eyes with glaucoma and suspected glaucoma.</div></div><div><h3>Design</h3><div>Prospective cohort study.</div></div><div><h3>Participants</h3><div>One hundred twenty-four eyes (91 eyes with glaucoma, 33 eyes with suspected glaucoma) of 64 patients (mean age, 68.4 ± 7.6 years) followed up at the Bascom Palmer Eye Institute, Palm Beach Gardens, Florida.</div></div><div><h3>Methods</h3><div>Participants underwent ophthalmic examination, BP measurement, and SAP at 4-month intervals. At the baseline visit, 24-hour ambulatory blood pressure monitoring (ABPM) was acquired. Linear mixed models (adjusted for inclusion of both eyes, age, sex, race, intraocular pressure, baseline severity, and central corneal thickness) were used to investigate the effect of BP on the rates of SAP mean deviation (MD) change over time.</div></div><div><h3>Main Outcome Measures</h3><div>Effect of baseline 24-hour and follow-up mean arterial pressure (MAP), systolic BP (SBP), and diastolic BP on change in SAP MD.</div></div><div><h3>Results</h3><div>Eyes underwent an average of 8.9 ± 1.5 SAP examinations over 28.3 ± 6.0 months of follow-up. The median rate of MD change was 0.14 dB/year (range, –1.21 to 0.96 dB/year) with 9 eyes (7%) showing moderate to fast progression (MD change, ≤ –0.50 dB/year). Each 10 mmHg lower in 24-hour average MAP and SBP were associated with –0.171 dB/year (<em>P</em> = 0.045) and –0.137 dB/year (<em>P</em> = 0.023) faster rates of MD loss. Lower mean SBP during follow-up was associated significantly (<em>P</em> = 0.003) with MD progression.</div></div><div><h3>Conclusions</h3><div>Lower baseline 24-hour ABPM measurements, as well as low SBP during follow-up, were associated significantly with faster rates of glaucomatous SAP progression and may be used as a predictor of risk of glaucomatous progression.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 1","pages":"Pages 30-38"},"PeriodicalIF":13.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"期刊一览","authors":"Sandeep Ravindran PhD","doi":"10.1016/j.ophtha.2024.11.009","DOIUrl":"10.1016/j.ophtha.2024.11.009","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 1","pages":"Page e2"},"PeriodicalIF":13.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe, Rebound Mpox in an Immunocompromised Man","authors":"Adam J. Neuhouser MD,&nbsp;Alisha Kamboj MD, MBA","doi":"10.1016/j.ophtha.2024.01.026","DOIUrl":"10.1016/j.ophtha.2024.01.026","url":null,"abstract":"","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 1","pages":"Page e13"},"PeriodicalIF":13.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139900253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}